Cargando…
Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy
COVID-19 is a rapidly evolving emergency, which necessitates scientific community to come up with novel formulations that could find quick relief to the millions affected around the globe. Remdesivir being the only injectable drug by FDA for COVID-19, it initially showed promising results, however,...
Autores principales: | Rejinold, N. Sanoj, Piao, Huiyan, Jin, Geun-woo, Choi, Goeun, Choy, Jin-Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383483/ https://www.ncbi.nlm.nih.gov/pubmed/34482191 http://dx.doi.org/10.1016/j.colsurfb.2021.112063 |
Ejemplares similares
-
Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
por: Choi, Goeun, et al.
Publicado: (2021) -
NICLOSAMIDE-EXFOLIATED ANIONIC CLAY NANOHYBRID REPURPOSED AS AN ANTIVIRAL DRUG FOR TACKLING COVID-19; ORAL FORMULATION WITH TWEEN 60/EUDRAGIT S100
por: Rejinold, N. Sanoj, et al.
Publicado: (2021) -
Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19
por: Rejinold N, Sanoj, et al.
Publicado: (2021) -
Niclosamide encapsulated in mesoporous silica and geopolymer: A potential oral formulation for COVID-19
por: Piao, Huiyan, et al.
Publicado: (2021) -
Inorganic–inorganic nanohybrids for drug delivery, imaging and photo-therapy: recent developments and future scope
por: Choi, Goeun, et al.
Publicado: (2021)